Medication info
Linagliptin Metformin Sustained Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Linagliptin Metformin Sustained Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›2.5mg / 1 tablet
Manufacturer / importer
Korea Hutech Pharmaceutical Co., Ltd.
Appearance
Oval sustained release tablet, white to almost white, engraved with LD21 on one side
Packaging
28 tablets/box (7 tablets/PTP x 4)
Approval status
Active

MFDS item code 202400620 · Approved 2024.03.22 · Insurance code 649105950

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically after administration of this drug. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.

Ingredients

Manufacturer
Korea Hutech Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is prescribed to assist patients with type 2 diabetes in blood sugar control when linagliptin and metformin need to be used together. Taking this medication alongside dietary changes and exercise can significantly aid in blood sugar management. Therefore, it is used effectively for controlling blood sugar in type 2 diabetes treatment.

How to take

Adult dose

The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically after administration of this drug. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.

Precautions

This medication helps to control blood sugar levels. However, it can rarely cause lactic acidosis, a dangerous condition due to the buildup of lactic acid in the body, so caution is required. It should not be used in individuals with allergies to this medication, type 1 diabetes, severe kidney dysfunction, liver dysfunction, acute infections, dehydration, or acute cardiac problems. Pregnant women or those with placental dysfunction should also avoid this medication. There is a risk of hypoglycemia when taking this medication, especially when used in combination with insulin or other antidiabetic agents, so blood sugar levels must be monitored closely. Patients with reduced kidney function should undergo regular kidney function tests, and this medication should not be used in cases of severe kidney impairment. Additionally, the medication should be temporarily discontinued before and after acute surgery or radiological examinations and can be resumed once kidney function has returned to normal. Rare side effects such as pancreatitis or skin blistering similar to pemphigus may occur, so if severe abdominal pain or skin abnormalities arise during treatment, the doctor should be informed immediately. Long-term use may lower vitamin B12 levels, so vitamin B12 testing should be done if symptoms of anemia or neurological abnormalities occur. This medication should be swallowed whole without breaking, chewing, or crushing. The outer shell of the tablet may appear in stool, which is normal. Additionally, this medication may interact with other drugs, so if other medications are being taken, it's essential to consult with a doctor or pharmacist. Elderly individuals are at higher risk of decreased kidney function, so appropriate dose adjustments and regular kidney function testing are necessary. Finally, overdosing on this medication may lead to serious side effects like lactic acidosis, so the prescribed dose must be strictly followed, and in case of overdose, immediate medical attention should be sought.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemia
  • dysgeusia
  • cough
  • loss of appetite
Show 126 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid
  • arthralgia with severe and disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity reactions
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's-type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • stomach cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hypertension
  • anxiety
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • confusional state
  • nocturia
  • dermatitis
  • hypertension
  • erectile dysfunction
  • goiter
  • vitreous hemorrhage
  • chest discomfort
  • weakness
  • pain
  • nosebleed
  • oropharyngeal pain
  • speech disorders
  • epistaxis
  • vocal cord polyp
  • dyslipidemia
  • hypercholesterolemia
  • osteoarthritis
  • limb pain
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • androgenetic alopecia
  • hyperhidrosis
  • hair loss
  • dermatitis
  • benign prostatic hyperplasia
  • dry eyes
  • cataracts
  • allergic conjunctivitis
  • dry eyes
  • cataracts
  • unstable angina
  • acute myocardial infarction
  • angina pectoris
  • unstable angina
  • cardiac arrest
  • palpitations
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • unstable angina
  • cardiac arrest

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is important to maintain storage temperatures between 1 and 30 degrees Celsius to safely preserve the medication's effectiveness.

Appearance and packaging

Appearance

Oval sustained release tablet, white to almost white, engraved with LD21 on one side

Package unit

28 tablets/box (7 tablets/PTP x 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.